Transforming Healthcare: Key Trends in South African Healthtech

By Crystal Lubbe

November 26, 2024

The South Africa healthcare technology sector is experiencing significant growth, driven by a combination of local innovation and international collaboration. Companies like CFAO Healthcare are making strategic investments, emphasising the sector’s expanding opportunities. CFAO Healthcare’s acquisition of Sanofi’s South African Consumer Healthcare business emphasises the increasing interest in healthcare technology within the region.

1. Expansion and Investments

CFAO Healthcare are actively moving into the South African market, which indicates a growing interest in the region’s healthcare technology sector. The acquisition of Sanofi’s South African Consumer Healthcare business by CFAO Healthcare highlights this trend.

2. Digital Health Innovations

South African healthtech startups, such as RecoMed, are securing significant funding to enhance digital healthcare services. RecoMed’s emphasis on streamlining appointment bookings and its specialisation in breast cancer care reflect the innovative approaches being embraced in the healthcare technology landscape.

3. Government Initiatives and Masterplans

The South African government has introduced a Medical Technology Masterplan aimed at enhancing the growth of the healthcare technology sector. This initiative seeks to improve regulatory frameworks, market growth, technology production, and research innovation, which are vital for developing local healthcare technologies.

4. Vaccine Manufacturing and Health Security

To enhance health security, efforts to improve vaccine manufacturing capabilities in South Africa are underway. Partnerships between Biovac and various development institutions are part of a broader strategy to increase local production of vaccines and reduce reliance on imports.

5. International Collaborations and Funding

There is a notable influx of international funding and partnerships in the South African healthcare technology sector. The Transform Health Fund, a $50 million pan-African initiative, is providing impact investments to health innovators across Sub-Saharan Africa, enhancing the development of healthcare technology in South Africa.

Implications for Healthcare Technology Companies

  • Market Growth: Increased investments and market expansion in South Africa reveal rising demand for healthcare technologies and business opportunities.
  • Innovation: Companies like RecoMed and EMGuidance show the potential of digital health to transform healthcare outcomes.
  • Regulatory Support: Government initiatives, such as the Medical Technology Masterplan, encourage investment and innovation in healthcare technology.
  • Global Partnerships: Collaborations with global organisations, like Eisai and Biovac, emphasize the importance of international partnerships in advancing healthcare.

These trends suggest significant growth for South Africa’s healthcare technology sector, offering opportunities to shape its future.

Reference url

Recent Posts

Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025

By Staff Writer

August 21, 2025

Type 2 diabetes management in adults is undergoing significant changes with the draft 2025 NICE guideline update. What are the main improvements in medication, monitoring, and patient care for adults with type 2 diabetes? The answer: The new NICE recommendations prioritize a broader use of SGL...
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit

By João L. Carapinha

August 19, 2025

A recent G-BA decision provides a systematic evaluation of Glofitamab Gemcitabine DLBCL, combined with Gemcitabine and Oxaliplatin (GemOx), for treating adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. The review...
Key Decisions on Health Technology Assessment at ACP124: Implications for Rare Disease Therapies
Health technology assessment (HTA) plays a crucial role in determining whether new therapies are reimbursed within healthcare systems. At the July 18, 2025 meeting of the Adviescommissie Pakket (ACP), two high-profile orphan drugs—omaveloxolone (Skyclarys®) for Friedreich’s ataxia and exagamgloge...